

Supplementary Table 3. Effect of MOI on GS-CA1 antiviral activity in a T-cell line

Multiplicity of Infection (MOI)	EC ₅₀ (nM) ^a				
	GS-CA1	TAF	EFV	DTG	DRV
0.01	0.034 ± 0.014	10.0 ± 4.5	0.69 ± 0.30	0.31 ± 0.13	1.36 ± 1.46
0.05	0.062 ± 0.027	12.8 ± 7.9	1.15 ± 0.34	0.50 ± 0.22	1.33 ± 0.70
0.25	0.160 ± 0.062	50.5 ± 48.5	2.79 ± 1.73	1.57 ± 1.10	2.67 ± 2.42
1.25	0.452 ± 0.174	61.1 ± 25.0	6.26 ± 1.22	2.46 ± 1.01	3.84 ± 1.60

^a EC₅₀ values (mean ± s.d.) obtained from triplicate cell cultures in each of 4 independent experiments. CEM-NK^R CCR5+Luc+ cells were infected with NL4-3-JRFL-secNLuc reporter HIV-1 at the indicated MOIs, treated with a dose-response of each inhibitor and developed with Nano-Glo Luciferase Assay reagent after 5 days of culture.

TAF = tenofovir alafenamide; EFV = efavirenz; DTG = dolutegravir; DRV = darunavir